Metoprolol
Treatment for Atrial Fibrillation
Typical Dosage: Metoprolol succinate 25-200 mg daily
Effectiveness
80%
Safety Score
70%
Clinical Trials
31
Participants
300K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
Metoprolol succinate 25-200 mg daily
Time to Effect
1-3 days
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75
Monitoring:$400
Side Effect Mgmt:$100
Total Annual:$575
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$5,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$676
Prescription Access Economics
Annual Societal Loss per Patient
$770
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$375/year
Time Cost
$270/year
Travel + wait time
Insurance Admin Cost
$80/year
Prior auth, claims
Rx Price
$75/year
Potential OTC Price
$30/year
Estimated if OTC available
Early Treatment Benefit
+0.10 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
MODERATEMissed Diagnosis Risk
LOWRequires Monitoring
YesNeeds lab work/checkups
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for Metoprolol in Atrial Fibrillation
Pharmacological Intervention to Prevent NOAF After TAVR
NCT07519161NOT YET RECRUITINGNA
198 participants
INTERVENTIONAL
Started: Apr 7, 2026
SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation
NCT07445789NOT YET RECRUITINGPHASE4
436 participants
INTERVENTIONAL
Started: Jun 1, 2026
Completed Clinical Trials
13 completed trials for Metoprolol in Atrial Fibrillation
Rate Control in Atrial Fibrillation II
NCT02695992COMPLETEDPHASE4
122 participants
INTERVENTIONAL
Rud, Norway
Started: Feb 1, 2016
Effect of BMS-914392 on Pharmacokinetics of Metoprolol
NCT01211821COMPLETEDPHASE1
18 participants
INTERVENTIONAL
Lenexa, United States
Started: Sep 1, 2010
PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer
NCT01281787COMPLETEDPHASE3
320 participants
INTERVENTIONAL
Milan, Italy
Started: Apr 1, 2008
RATe Control in Atrial Fibrillation
NCT00313157COMPLETEDPHASE3
80 participants
INTERVENTIONAL
Rud, Norway
Started: Apr 1, 2006
Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery
NCT00784316COMPLETEDPHASE4
316 participants
INTERVENTIONAL
Kuopio, Finland
Started: Aug 1, 2007
Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac Surgery
NCT03943927COMPLETEDNA
107 participants
INTERVENTIONAL
Nashville, United States
Started: Mar 5, 2021
Carvedilol Versus Metoprolol for the Prevention of Atrial Fibrillation After Off-Pump Coronary Bypass Surgery
NCT00198614COMPLETEDNA
650 participants
INTERVENTIONAL
Suita, Japan
Started: Jan 1, 2005
Diltiazem vs. Metoprolol in the Acute Management of AF in Patients With HFrEF
NCT02938260COMPLETED
48 participants
OBSERVATIONAL
Started: Oct 1, 2016
Intravenous Administration of Metoprolol Versus Biatrial Pacing in the Prevention of Atrial Fibrillation After Cardiac Surgery
NCT00783900COMPLETEDPHASE4
316 participants
INTERVENTIONAL
Kuopio, Finland
Started: Jan 1, 2007
Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery
NCT00953212COMPLETEDPHASE3
304 participants
INTERVENTIONAL
Portland, United States
Started: Aug 1, 2009
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
NCT01970501COMPLETEDPHASE2
267 participants
INTERVENTIONAL
Anchorage, United States +96 more
Started: Apr 1, 2014
Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department
NCT02248753COMPLETEDNA
437 participants
INTERVENTIONAL
Amsterdam, Netherlands +14 more
Started: Oct 1, 2014
Rate Control in Atrial Fibrillation
NCT01655303COMPLETEDPHASE4
90 participants
INTERVENTIONAL
Tehran, Iran
Started: Feb 1, 2011
Showing 20 of 34 total trials